These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16686067)

  • 1. [Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].
    Zhao M; Xiao SW; Yang JX; Zhang SW; Lü YY
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3495-8. PubMed ID: 16686067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases].
    Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Cai Y; Zhu GY; Xu B; Lü YY
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2023-8. PubMed ID: 14703408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up].
    Han DM; Huang ZG; Zhang W; Yu ZK; Wang Q; Ni X; Chen XH; Pan JH; Wang H
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2029-32. PubMed ID: 14703409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
    Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
    Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression.
    Hanazono K; Natsugoe S; Stein HJ; Aikou T; Hoefler H; Siewert JR
    Oncol Rep; 2006 Apr; 15(4):821-4. PubMed ID: 16525665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
    Swisher SG; Roth JA; Komaki R; Gu J; Lee JJ; Hicks M; Ro JY; Hong WK; Merritt JA; Ahrar K; Atkinson NE; Correa AM; Dolormente M; Dreiling L; El-Naggar AK; Fossella F; Francisco R; Glisson B; Grammer S; Herbst R; Huaringa A; Kemp B; Khuri FR; Kurie JM; Liao Z; McDonnell TJ; Morice R; Morello F; Munden R; Papadimitrakopoulou V; Pisters KM; Putnam JB; Sarabia AJ; Shelton T; Stevens C; Shin DM; Smythe WR; Vaporciyan AA; Walsh GL; Yin M
    Clin Cancer Res; 2003 Jan; 9(1):93-101. PubMed ID: 12538456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia.
    Zhang S; Li Y; Li L; Zhang Y; Gao N; Zhang Z; Zhao H
    J Oral Maxillofac Surg; 2009 May; 67(5):1074-82. PubMed ID: 19375021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
    Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
    Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II clinical trial].
    Chen CB; Pan JJ; Xu LY
    Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2033-5. PubMed ID: 14703410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
    Pan JJ; Zhang SW; Chen CB; Xiao SW; Sun Y; Liu CQ; Su X; Li DM; Xu G; Xu B; Lu YY
    J Clin Oncol; 2009 Feb; 27(5):799-804. PubMed ID: 19103729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.
    von Brevern MC; Hollstein MC; Cawley HM; De Benedetti VM; Bennett WP; Liang L; He AG; Zhu SM; Tursz T; Janin N; Trivers GE
    Cancer Res; 1996 Nov; 56(21):4917-21. PubMed ID: 8895744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
    Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
    Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
    Yen N; Ioannides CG; Xu K; Swisher SG; Lawrence DD; Kemp BL; El-Naggar AK; Cristiano RJ; Fang B; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Merritt JA; Mukhopadhyay T; Nesbitt JC; Nguyen D; Perez-Soler R; Pisters KM; Putnam JB; Schrump DS; Shin DM; Walsh GL; Roth JA
    Cancer Gene Ther; 2000 Apr; 7(4):530-6. PubMed ID: 10811470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
    Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
    Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].
    Zhang SW; Xiao SW; Liu CQ; Sun Y; Su X; Li DM; Xu G; Zhu GY; Xu B
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):426-8. PubMed ID: 16188130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.